Skip to main
BCYC
BCYC logo

BCYC Stock Forecast & Price Target

BCYC Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 47%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Bicycle Therapeutics PLC is experiencing a positive outlook due to the promising Phase 1 results from its product candidate BT8009, which has increased the probability of success in key oncology indications to 40%. Additionally, the company's advanced clinical assets, BT8009 and BT5528, have demonstrated acceptable safety and efficacy in treating urothelial and ovarian cancers, potentially distinguishing them from existing therapies. Furthermore, rapid enrollment in the Duravelo-2 trials is exceeding expectations, indicating strong interest and viability in its drug development pipeline.

Bears say

Bicycle Therapeutics PLC faces a negative outlook primarily due to the uncertain future of its product candidate, BT8009, which may yield lower-than-expected Phase 1 results and a projected 0% probability of success, significantly devaluing the company’s asset base. The company has reported disappointing clinical data for its therapeutic candidates in triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC), contributing to concerns over the sales potential of its products amidst increasing competitive pressures. Additionally, elevated selling, general, and administrative (SG&A) expenses, reported at $21.6 million, exceeded both analyst estimates and consensus, underscoring financial risks associated with the company's capital-intensive development initiatives.

BCYC has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 47% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bicycle Therapeutics Plc - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bicycle Therapeutics Plc - ADR (BCYC) Forecast

Analysts have given BCYC a Buy based on their latest research and market trends.

According to 17 analysts, BCYC has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bicycle Therapeutics Plc - ADR (BCYC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.